Stratification analysis and case-control study of relationships between interleukin-6 gene polymorphisms and cervical cancer risk in a Chinese population

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 17, 2014, Pages 7357-7362

  Shi, Wen Jing ^a   Liu, Hao ^b   Wu, Dan ^a   Tang, Zhen Hua ^a   Shen, Yu Chen ^a   Guo, Lin ^c  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b HONG KONG POLYTECHNIC UNIVERSITY   (Hong Kong)

^c FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

Author keywords

Cervical cancer; Chinese females; Gene polymorphism; Interleukin 6; Risk

Indexed keywords

IL6 PROTEIN, HUMAN; INTERLEUKIN 6;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CANCER STAGING; CARCINOMA; CASE CONTROL STUDY; CHINA; FEMALE; GENETIC PREDISPOSITION; GENETICS; HUMAN; MIDDLE AGED; PATHOLOGY; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX TUMOR;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; CERVICAL INTRAEPITHELIAL NEOPLASIA; CHINA; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTERLEUKIN-6; MIDDLE AGED; NEOPLASM STAGING; UTERINE CERVICAL NEOPLASMS;

EID: 84907276963     PISSN: 15137368     EISSN: None     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.17.7357     Document Type: Article

References (37)

1. Barbisan G, Perez LO, Contreras A, Golijow CD (2012). TNF-α and IL-10 promoter polymorphisms, HPV infection, and cervical cancer risk. Tumour Biol, 33, 1549-56.
2. Bennermo M, Held C, Green F, et al (2004). Prognostic value of plasma interleukin-6 concentrations and the-174 G>C and-572 G>C promoter polymorphisms of the interleukin-6 gene in patients with acute myocardial infarction treated with thrombolysis. Atherosclerosis, 174, 157-63.
3. Bowcock AM, Kidd JR, Lathrop GM, et al (1988). The human “interferon-beta 2/hepatocyte stimulating factor/interleukin-6“ gene: DNA polymorphism studies and localization to chromosome 7p21. Genomics, 3, 8-16.
4. Castro FA, Haimila K, Sareneva I, et al (2009). Association of HLA-DRB1, interleukin-6 and cyclin D1 polymorphisms with cervical cancer in the Swedish population-a candidate gene approach. Int J Cancer, 125, 1851-8.
5. Crosbie EJ, Einstein MH, Franceschi S, Kitchener HC (2013). Human papillomavirus and cervical cancer. Lancet, 382, 889-99.
6. Fishman D, Faulds G, Jeffery R, et al (1998). The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest, 102, 1369-76.
7. Gangwar R, Mittal B, Mittal RD (2009). Association of interleukin-6-174G>C promoter polymorphism with risk of cervical cancer. Int J Biol Markers, 24, 11-6.
8. Grimm C, Six L, Tomovski C, et al (2005). A common interleukin-6 promoter polymorphism in patients with vulvar cancer. J Soc Gynecol Investig, 12, 617-20.
9. Grimm C, Watrowski R, Baumühlner K, et al (2011). Genetic variations of interleukin-1 and-6 genes and risk of cervical intraepithelial neoplasia. Gynecol Oncol, 121, 537-41.
10. Hamaguchi M, Kawahito Y, Ishino H, et al (2011). Mucin from rheumatoid arthritis synovial fluid enhances interleukin-6 production by human peripheral blood mononuclear cells. Hum Immunol, 72, 241-8.
11. Huang D, Zheng C, Giscombe R, et al (1999). Polymorphisms at-174 and in the 3' flanking region of interleukin-6 (IL-6) gene in patients with myasthenia gravis. J Neuroimmunol, 101, 197-200.
12. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.
13. Kyo S, Kanaya T, Takakura M, Inoue M (2000). A case of cervical cancer with aggressive tumor growth: possible autocrine growth stimulation by G-CSF and IL-6. Gynecol Oncol, 78, 383-7.
14. Landi S, Moreno V, Gioia-Patricola L, et al (2003). Association of common polymorphisms in inflammatory genes interleukin (IL)6, IL8, tumor necrosis factor alpha, NFKB1, and peroxisome proliferator-activated receptor gamma with colorectal cancer. Cancer Res, 63, 3560-6.
15. Liu D, Zhou P, Zhang L, et al (2011). Differential expression of oct4 in hpv-positive and hpv-negative cervical cancer cells is not regulated by DNA methyltransferase 3a. Tumour Biol, 32, 941-50.
16. Ma Y, Tang RK, Yang X, et al (2011). Lack of an association between interleukin-6 gene promoter polymorphisms (-174G/C,-572G/C) and ischemic heart disease and/or ischemic stroke: a meta-analysis. Hum Immunol, 72, 641-51.
17. Magalhães JF, Cortinhas AJ, Albuquerque CM, et al (2013). Interleukin-6 gene-174G>C and-636G>C promoter polymorphisms and prostate cancer risk. Mol Biol Rep, 40, 449-55.
18. Mosaad YM, Fathy H, Fawzy Z, El-Saied MA (2012). Tumor necrosis factor-α-308 G>A and interleukin-6-174 G>C promoter polymorphisms and pemphigus. Hum Immunol, 73, 560-5.
19. Ni J, Ye Y, Teng F, Wu Q (2013). Interleukin 10 polymorphisms and cervical cancer risk: a meta-analysis. Int J Gynecol Cancer, 23, 126-33.
20. Nogueira de Souza NC, Brenna SM, Campos F, et al (2006). Interleukin-6 polymorphisms and the risk of cervical cancer. Int J Gynecol Cancer, 16, 1278-82.
21. Shi TY, Zhu ML, He J, et al (2013). Polymorphisms of the interleukin 6 gene contribute to cervical cancer susceptibility in eastern Chinese women. Hum Genet, 132, 301-12.
22. Shuai HL, Luo X, Yan RL, Li J, Chen DL (2012). XRCC1 polymorphisms are associated with cervical cancer risk and response to chemotherapy: a systematic review and meta-analysis. Asian Pac J Cancer Prev, 13, 6423-7.
23. Slattery ML, Curtin K, Sweeney C, Wolff RK, Baumgartner RN, Baumgartner KB, Giuliano AR, Byers T (2008). Modifying effects of IL-6 polymorphisms on body size-associated breast cancer risk. Obesity, 16, 339-47.
24. Srivani R, Nagarajan B (2003). A prognostic insight on in vivo expression of interleukin-6 in uterine cervical cancer. Int J Gynecol Cancer, 13, 331-9.
25. Tao QS, Huang HL, Chai Y, et al (2012). Interleukin-6 up-regulates the expression of interleukin-15 is associated with MAPKs and PI3-K signaling pathways in the human keratinocyte cell line, HaCaT. Mol Biol Rep, 39, 4201-5.
26. Tjiong MY, van der Vange N, ten Kate FJ, et al (1999). Increased IL-6 and IL-8 levels in cervicovaginal secretions of patients with cervical cancer. Gynecol Oncol, 73, 285-91.
27. Upadhyay R, Jain M, Kumar S, Ghoshal UC, Mittal B (2008). Association of interleukin-6 (-174G>C) promoter polymorphism with risk of squamous cell esophageal cancer and tumor location: an exploratory study. Clin Immunol, 128, 199-204.
28. Vairaktaris E, Yiannopoulos A, Vylliotis A, et al (2006). Strong association of interleukin-6-174 G>C promoter polymorphism with increased risk of oral cancer. Int J Biol Markers, 21, 246-50.
29. Wei LH, Kuo ML, Chen CA, et al (2001a). Interleukin-6 in cervical cancer: the relationship with vascular endothelial growth factor. Gynecol Oncol, 82, 49-56.
30. Wei LH, Kuo ML, Chen CA, et al (2001b). The anti-apoptotic role of interleukin-6 in human cervical cancer is mediated by up-regulation of Mcl-1 through a PI 3-K/Akt pathway. Oncogene, 20, 5799-809.
31. Xu B, Niu XB, Wang ZD, et al (2011). IL-6-174G>C polymorphism and cancer risk: a meta-analysis involving 29, 377 cases and 37, 739 controls. Mol Biol Rep, 38, 2589-96.
32. Yang S, Jia C, Zhu H, Han S (2012). CYP1A1 Ile462Val polymorphism and cervical cancer: evidence from a meta-analysis. Tumour Biol, 33, 2265-72.
33. Zhang H, Xu Y, Li L, Liu R, Ma B (2012). The interleukin-6-174G/C polymorphism and prostate cancer risk: a systematic review and meta-analysis. Urol Int, 88, 447-53.
34. Zhang HL, Zhang YJ (2013). A systemic assessment of the association between tumor necrosis factor alpha 308 G/A polymorphism and risk of cervical cancer. Tumor Biol, 34, 1659-65.
35. Zhang ZY, Jin XY, Wu R, et al (2012). Meta-analysis of the association between GSTM1 and GSTT1 gene polymorphisms and cervical cancer. Asian Pac J Cancer Prev, 13, 815-9.
36. Zhou X, Gu Y, Zhang SL (2012). Association between p53 codon 72 polymorphism and cervical cancer risk among Asians: a HuGE review and meta-analysis. Asian Pac J Cancer Prev, 13, 4909-14.
37. Zhu J, Wu L, Kohlmeier M, Ye F, Cai W (2013). Association between MTHFR C677T, MTHFR A1298C and MS A2756G polymorphisms and risk of cervical intraepithelial neoplasia II/III and cervical cancer: a meta-analysis. Mol Med Rep, 8, 919-27.